| Identification | Back Directory | [Name]
Edatrexate | [CAS]
80576-83-6 | [Synonyms]
EDX
CGP 30694
NSC 626715
Edatrexate
PSYLLIUMSEED
FSIRXIHZBIXHKT-MHTVFEQDSA-N
10-Ethyl-10-deazaaminopterin
10-Ethyl-10-deazaaminopterine
N-[4-[1-[(2,4-Diaminopteridin-6-yl)methyl]propyl]benzoyl]-L-glutamic acid
N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)propyl)benzoyl)-L-glutamic acid
L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]propyl]benzoyl]-
2-[[4-[1-(2,4-Diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid
(S)-2-[4-[1-[(2,4-Diaminopteridine-6-yl)methyl]propyl]benzoylamino]pentanedioic acid | [Molecular Formula]
C22H25N7O5 | [MDL Number]
MFCD00866254 | [MOL File]
80576-83-6.mol | [Molecular Weight]
467.48 |
| Hazard Information | Back Directory | [Uses]
Antineoplastic. | [Definition]
ChEBI: Edatrexate is a glutamic acid derivative. | [in vivo]
Edatrexate (0.14 g/kg and 0.21 g/kg; i.p.; twice weekly×3 or weekly×3) exerts potent efficacy against advanced metastatic disease in tumor-bearing mice, better than MTX[1].
| Animal Model: | Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma)[2] | | Dosage: | 0.14 g/kg and 0.21 g/kg | | Administration: | Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment | | Result: | Increased survival of tumor-bearing mice.
Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue. |
|
|
| Company Name: |
SIMAGCHEM CORP
|
| Telephone: |
+86-5922680277 +86-13806087780 |
| Website: |
http://www.simagchem.com/ |
|